$PBLA
Panbela Therapeutics, Inc. Stock $pbla

$pbla Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-K Financial Statement

#000143774918005094 Filed on March 21, 2018

Income Statement

Concept	2016 Q4	2016	2015 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.270M	$2.660M	$370.0K
YoY Change	243.24%	2.7%	54.17%
% of Gross Profit
Research & Development	$850.0K	$2.504M	$920.0K
YoY Change	-7.61%	-12.2%	37.31%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.110M	$2.504M	$1.280M
YoY Change	64.84%	-12.2%	39.13%
Operating Profit		-$5.168M
YoY Change		-5.07%
Interest Expense	-$50.00K	$180.0K	-$60.00K
YoY Change	-16.67%	-1.64%	-14.29%
% of Operating Profit
Other Income/Expense, Net	-$170.0K	-$285.0K	-$20.00K
YoY Change	750.0%	19.25%	-33.33%
Pretax Income	-$2.330M	-$5.453M	-$1.370M
YoY Change	70.07%	-4.05%	34.31%
Income Tax	-$90.00K	-$341.0K	-$640.0K
% Of Pretax Income
Net Earnings	-$2.240M	-$5.112M	-$730.0K
YoY Change	206.85%	3.75%	-25.51%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$695.7K	-$1.643M	-$237.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$440.0K	$440.0K	$930.0K
YoY Change	-52.69%	-52.69%	-56.74%
Cash & Equivalents	$438.0K	$440.0K	$925.0K
Short-Term Investments
Other Short-Term Assets	$120.0K	$120.0K	$70.00K
YoY Change	71.43%	71.43%	250.0%
Inventory
Prepaid Expenses	$118.0K		$74.00K
Receivables
Other Receivables
Total Short-Term Assets	$877.0K	$880.0K	$1.732M
YoY Change	-49.36%	-49.13%	-27.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$76.00K
YoY Change			-27.62%
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL ASSETS
Total Short-Term Assets	$877.0K	$880.0K	$1.732M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$877.0K	$880.0K	$1.732M
YoY Change	-49.36%	-49.13%	-30.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.245M	$1.250M	$585.0K
YoY Change	112.82%	111.86%	96.97%
Accrued Expenses	$842.0K	$1.000M	$505.0K
YoY Change	66.73%	85.19%	282.58%
Deferred Revenue
YoY Change
Short-Term Debt	$250.0K	$250.0K	$250.0K
YoY Change	0.0%	0.0%
Long-Term Debt Due	$294.0K	$3.030M
YoY Change
Total Short-Term Liabilities	$5.519M	$5.520M	$1.375M
YoY Change	301.38%	300.0%	194.43%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$287.0K
YoY Change		-100.0%	-4.33%
Other Long-Term Liabilities	$0.00	$0.00	$40.00K
YoY Change	-100.0%	-100.0%	33.33%
Total Long-Term Liabilities		$0.00	$3.038M
YoY Change		-100.0%	-8.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.519M	$5.520M	$1.375M
Total Long-Term Liabilities		$0.00	$3.038M
Total Liabilities	$5.519M	$5.520M	$4.413M
YoY Change	25.06%	25.17%	16.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.78M		-$13.67M
YoY Change	37.4%		59.49%
Common Stock	$3.000K		$30.00K
YoY Change	-90.0%		400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.642M	-$4.640M	-$2.681M
YoY Change
Total Liabilities & Shareholders Equity	$877.0K	$880.0K	$1.732M
YoY Change	-49.36%	-49.13%	-30.1%

Cashflow Statement

Concept	2016 Q4	2016	2015 Q4
OPERATING ACTIVITIES
Net Income	-$2.240M	-$5.112M	-$730.0K
YoY Change	206.85%	3.75%	-25.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$830.0K	-$2.398M	-$860.0K
YoY Change	-3.49%	-38.51%	-26.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	1.915M	0.000
YoY Change		-28.54%	-100.0%
NET CHANGE
Cash From Operating Activities	-830.0K	-2.398M	-860.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	50.00K	1.915M	0.000
Net Change In Cash	-780.0K	-483.0K	-860.0K
YoY Change	-9.3%	-32.92%	-31.75%
FREE CASH FLOW
Cash From Operating Activities	-$830.0K	-$2.398M	-$860.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	snbp	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	42000
CY2017	snbp	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	19000
CY2017	snbp	Changes In Gross Deferred Tax Assets Due To Changes In Enacted Tax Rate ChangesInGrossDeferredTaxAssetsDueToChangesInEnactedTaxRate	-1800000
CY2017Q4	snbp	Clinical Trial Related Liabilities Current ClinicalTrialRelatedLiabilitiesCurrent	95000
CY2016Q4	snbp	Clinical Trial Related Liabilities Current ClinicalTrialRelatedLiabilitiesCurrent	97000
CY2017Q4	snbp	Common Shares Issued Upon Conversion Of Notes Payable CommonSharesIssuedUponConversionOfNotesPayable	319193
CY2017	snbp	Debt Conversion Conversion Of Demand Notes Into Common Stock DebtConversionConversionOfDemandNotesIntoCommonStock	250000
CY2016	snbp	Debt Conversion Conversion Of Demand Notes Into Common Stock DebtConversionConversionOfDemandNotesIntoCommonStock
CY2017	snbp	Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock	2888000
CY2016	snbp	Debt Conversion Conversion Of Promissory Notes And Accrued Interest Into Common Stock DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock
CY2016Q3	snbp	Deferred Compensation Exchanged For Common Stock And Warrants DeferredCompensationExchangedForCommonStockAndWarrants	196000
CY2017	snbp	Deferred Compensation Exchanged For Common Stock And Warrants DeferredCompensationExchangedForCommonStockAndWarrants
CY2016	snbp	Deferred Compensation Exchanged For Common Stock And Warrants DeferredCompensationExchangedForCommonStockAndWarrants	196000
CY2017Q4	snbp	Deferred Tax Assets Gross Net Of Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsGrossNetOfDeferredTaxLiabilitiesBeforeValuationAllowance	4079000
CY2016Q4	snbp	Deferred Tax Assets Gross Net Of Deferred Tax Liabilities Before Valuation Allowance DeferredTaxAssetsGrossNetOfDeferredTaxLiabilitiesBeforeValuationAllowance	4472000
CY2017Q4	snbp	Deferred Tax Liabilities Beneficial Conversion Feature Net DeferredTaxLiabilitiesBeneficialConversionFeatureNet	338000
CY2016Q4	snbp	Deferred Tax Liabilities Beneficial Conversion Feature Net DeferredTaxLiabilitiesBeneficialConversionFeatureNet
CY2017	snbp	Effective Income Tax Rate Reconciliation Deferred True Up Percent EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent	0.03
CY2016	snbp	Effective Income Tax Rate Reconciliation Deferred True Up Percent EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
CY2017	snbp	Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent	0.038
CY2016	snbp	Effective Income Tax Rate Reconciliation Foreign Research Incentives Percent EffectiveIncomeTaxRateReconciliationForeignResearchIncentivesPercent
CY2017	snbp	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.135
CY2016	snbp	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.04
CY2017	snbp	Effective Income Tax Rate Reconciliation State Tax True Up Rate Percent EffectiveIncomeTaxRateReconciliationStateTaxTrueUpRatePercent
CY2016	snbp	Effective Income Tax Rate Reconciliation State Tax True Up Rate Percent EffectiveIncomeTaxRateReconciliationStateTaxTrueUpRatePercent	0.006
CY2017Q4	snbp	Grant Agreement Total Grants GrantAgreementTotalGrants	225000
CY2017	snbp	Grant Income Nonoperating GrantIncomeNonoperating	163000
CY2016	snbp	Grant Income Nonoperating GrantIncomeNonoperating
CY2017	snbp	Increase Decrease In Income And Other Taxes Receivable IncreaseDecreaseInIncomeAndOtherTaxesReceivable	70000
CY2016	snbp	Increase Decrease In Income And Other Taxes Receivable IncreaseDecreaseInIncomeAndOtherTaxesReceivable	-426000
CY2017	snbp	Intrinsic Value Of Convertible Debt With Conversion Feature IntrinsicValueOfConvertibleDebtWithConversionFeature	2954000
CY2016	snbp	Intrinsic Value Of Convertible Debt With Conversion Feature IntrinsicValueOfConvertibleDebtWithConversionFeature
CY2017	snbp	Noncash Interest Expense NoncashInterestExpense	162000
CY2016	snbp	Noncash Interest Expense NoncashInterestExpense	12000
CY2017Q4	snbp	Product And Process Development Liabilities Current ProductAndProcessDevelopmentLiabilitiesCurrent
CY2016Q4	snbp	Product And Process Development Liabilities Current ProductAndProcessDevelopmentLiabilitiesCurrent	29000
CY2017Q4	snbp	Reduction Of Shares Authorized Percent ReductionOfSharesAuthorizedPercent	0.5
CY2016	snbp	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod	385600
CY2017	snbp	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod	54000
CY2016	snbp	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Available For Grant Shares Reserved SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesReserved	889774
CY2017	snbp	Stock Issued During Period Value Conversion Of Demand Notes Payable StockIssuedDuringPeriodValueConversionOfDemandNotesPayable	-993000
CY2017Q4	snbp	Working Capital WorkingCapital	-3400000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1196000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1245000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	61000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	902000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1733000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	495000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	557000
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75000
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1387000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-165000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	76000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25625000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14058000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	2954000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1254000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	842000
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	56000
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1204653
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1310126
CY2017Q4	us-gaap	Assets Assets	767000
CY2016Q4	us-gaap	Assets Assets	877000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	767000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	877000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	152000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	438000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	925000
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-286000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-487000
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	151500
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2265053
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3841652
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3220100
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3841652
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3220100
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.003
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.001
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1094000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	637000
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1000000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1900000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10615000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5049000
CY2017Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of </div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> Cash is deposited in demand accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses on its deposits of cash.</div></div></div></div></div>
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1525000
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2733000
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3440000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3550000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	79000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	235000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	235000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	530000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	420000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	236000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	188000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4079000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4472000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	24000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.91
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.65
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	10000
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.038
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.066
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.307
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.172
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3423000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2664000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10910000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5453000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-536000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-341000
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	420000
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	321000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-319000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	726000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	402000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	601000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	75000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19000
CY2017	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	3696000
CY2016	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense
CY2017	us-gaap	Interest Expense InterestExpense	1617000
CY2016	us-gaap	Interest Expense InterestExpense	180000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	11000
CY2016	us-gaap	Interest Paid Net InterestPaidNet	57000
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	181000
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	155000
CY2017	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1000
CY2016	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	767000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	877000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4170000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5519000
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	286000
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	14000
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	294000
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	286000
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Risks and Uncertainties</div></div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have incurred losses of $<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29.2</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011.</div> For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>we incurred a net loss and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.4</div> million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>we had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$152,000,</div> negative working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.4</div> million and stockholders’ deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.7</div> million. The Company’s principal sources of cash have included the issuance of convertible debt and equity securities. </div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101,</div> in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> entitled “Liquidity and Management’s Plans.”</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div>
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3106000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1915000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3402000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2398000
	us-gaap	Net Income Loss NetIncomeLoss	-29200000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-10374000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-5112000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4894000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-285000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-6016000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-5168000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	470000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	970000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-241000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	63000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	255000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-107000
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	16000
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	152000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	195000
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	118000
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3059000
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1873000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	19000
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	42000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2593000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2504000
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29153000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18779000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1733000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	902000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1060400
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	610226
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1114400
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	30000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	385600
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	54000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23300785
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3896235
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2121985
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	346360
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	701960
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	733960
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.70
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.50
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.79
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.25
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.18
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.10
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	598760
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	733960
CY2017Q4	us-gaap	Share Price SharePrice
CY2016Q4	us-gaap	Share Price SharePrice	15.10
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	298400
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	135200
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	9.47
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	9.31
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	217200
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	8.79
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y295D
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	9.79
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y317D
CY2017	us-gaap	Stock Issued1 StockIssued1
CY2016	us-gaap	Stock Issued1 StockIssued1	75000
CY2016Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	3750
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	22000
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5841000
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	75000
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2069000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-3689000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-4642000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-2681000
CY2016Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	250000
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div>
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3566098
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3106846

Files In Submission

Name	View Source	Status
0001437749-18-005094-index-headers.html	Edgar Link	pending
0001437749-18-005094-index.html	Edgar Link	pending
0001437749-18-005094.txt	Edgar Link	pending
0001437749-18-005094-xbrl.zip	Edgar Link	pending
ex_108062.htm	Edgar Link	pending
ex_108063.htm	Edgar Link	pending
ex_108269.htm	Edgar Link	pending
ex_108270.htm	Edgar Link	pending
ex_108271.htm	Edgar Link	pending
ex_108272.htm	Edgar Link	pending
figure1.jpg	Edgar Link	pending
figure2.jpg	Edgar Link	pending
figure3.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snbp-20171231.xml	Edgar Link	completed
snbp-20171231.xsd	Edgar Link	pending
snbp-20171231_cal.xml	Edgar Link	unprocessable
snbp-20171231_def.xml	Edgar Link	unprocessable
snbp-20171231_lab.xml	Edgar Link	unprocessable
snbp-20171231_pre.xml	Edgar Link	unprocessable
snbp20171231_10k.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBLA
Panbela Therapeutics, Inc. Stock $pbla

2016 Q4 Form 10-K Financial Statement

#000143774918005094 Filed on March 21, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBLA Panbela Therapeutics, Inc. Stock $pbla

2016 Q4 Form 10-K Financial Statement

#000143774918005094 Filed on March 21, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBLA
Panbela Therapeutics, Inc. Stock $pbla